Skip to Content
Merck
  • Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.

Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.

Cancer research (2014-07-20)
Gregory J Baker, Peter Chockley, Viveka Nand Yadav, Robert Doherty, Michael Ritt, Sivaraj Sivaramakrishnan, Maria G Castro, Pedro R Lowenstein
ABSTRACT

Natural killer (NK) cells safeguard against early tumor formation by destroying transformed target cells in a process referred to as NK immune surveillance. However, the immune escape mechanisms used by malignant brain tumors to subvert this innate type of immune surveillance remain unclear. Here we show that malignant glioma cells suppress NK immune surveillance by overexpressing the β-galactoside-binding lectin galectin-1. Conversely, galectin-1-deficient glioma cells could be eradicated by host NK cells before the initiation of an antitumor T-cell response. In vitro experiments demonstrated that galectin-1-deficient GL26-Cit glioma cells are ∼3-fold more sensitive to NK-mediated tumor lysis than galectin-1-expressing cells. Our findings suggest that galectin-1 suppression in human glioma could improve patient survival by restoring NK immune surveillance that can eradicate glioma cells. Cancer Res; 74(18); 5079-90. ©2014 AACR.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® pLKO.1-puro Empty Vector Control Plasmid DNA, Contains no shRNA insert
Sigma-Aldrich
MISSION® pLKO.1-puro Non-Mammalian shRNA Control Plasmid DNA, Targets no known mammalian genes